Reglan (metoclopramide) is primarily indicated for the short-term management of symptomatic gastroesophageal reflux disease (GERD) and diabetic gastroparesis when motility enhancement is desired. It is also commonly used as an antiemetic to treat severe nausea and vomiting associated with chemotherapy, surgery, or migraine. By antagonizing dopamine receptors and enhancing acetylcholine release in the upper gastrointestinal tract, Reglan increases gastric emptying and improves coordination of gastrointestinal contractions, which can relieve symptoms such as bloating, early satiety, and persistent nausea.
Clinicians may also use metoclopramide off-label for diagnostic procedures (to improve gastric emptying before imaging) and as adjunctive therapy when other antiemetics are ineffective. Because of safety concerns with prolonged exposure, professional guidelines generally recommend restricting use to short durations and to situations where benefits outweigh the risks.
Adult oral dosing commonly starts at 5–10 mg taken 30 minutes before meals and, if needed, at bedtime. For gastroparesis, many prescribers use 10 mg up to four times daily, but treatment should typically be limited to short durations consistent with safety guidance. Intramuscular or intravenous administration is used in acute settings—doses vary by indication and clinical status. Pediatric dosing is weight-based and must be determined by a qualified clinician.
Dose adjustments are recommended for patients with renal impairment because metoclopramide is excreted renally. Older adults often require lower doses because they are more susceptible to central nervous system adverse effects and movement disorders. Always follow the specific dosing instructions provided by your prescribing clinician or the product label, and never increase the frequency or dose without medical advice.
The most serious safety concern with Reglan is the risk of tardive dyskinesia, an often irreversible movement disorder characterized by repetitive, involuntary movements. Risk increases with cumulative exposure and with prolonged or high-dose therapy. Because of this, regulatory agencies recommend limiting treatment to the shortest duration possible—typically no more than 12 weeks—unless clearly needed.
Other precautions include the potential for acute extrapyramidal symptoms (dystonia, akathisia) especially in younger patients and with parenteral administration. Patients with depression, Parkinson’s disease, or a history of movement disorders should be evaluated carefully prior to prescribing. Metoclopramide can also cause sedation and confusion; caution is advised when driving or operating machinery. Women who are pregnant or breastfeeding should discuss risks and benefits with a clinician; metoclopramide crosses the placenta and is excreted in breast milk.
Reglan should not be used in patients with known hypersensitivity to metoclopramide or any component of the formulation. It is contraindicated in gastrointestinal hemorrhage, mechanical obstruction, or perforation—conditions where stimulation of GI motility could be harmful. Reglan is also contraindicated in patients with a history of tardive dyskinesia related to metoclopramide and in those receiving concurrent medications known to cause extrapyramidal symptoms without careful monitoring.
Use is generally contraindicated in patients with uncontrolled seizure disorders because metoclopramide can lower the seizure threshold. Inform your healthcare provider about all medical conditions before starting therapy to ensure safety.
Common side effects include drowsiness, fatigue, restlessness, and gastrointestinal disturbances such as diarrhea. Acute extrapyramidal reactions—sustained muscle contractions, facial grimacing, torticollis—may occur, particularly in younger patients or with higher doses. These reactions often respond to anticholinergic agents (e.g., diphenhydramine) or benzodiazepines in acute care settings.
Less common but serious effects include tardive dyskinesia, neuroleptic malignant syndrome-like reactions, depression, and suicidal ideation. Cardiovascular effects such as hypotension and bradycardia have been reported in some cases. If you experience new or worsening involuntary movements, severe weakness, difficulty breathing, fainting, or chest pain, seek medical attention immediately.
Reglan interacts with several classes of medications. Concomitant use with other dopamine antagonists or neuroleptic drugs increases the risk of extrapyramidal symptoms and tardive dyskinesia. Metoclopramide can antagonize the effects of levodopa and other dopaminergic agents used in Parkinson’s disease, potentially reducing their therapeutic benefit.
CNS depressants, including alcohol, opioids, and benzodiazepines, may have additive sedative effects when used with metoclopramide. Use with caution and avoid hazardous activities until you know how the combination affects you. Additionally, drugs that affect renal clearance may alter metoclopramide levels; clinicians should review a full medication list to identify potential pharmacokinetic interactions. Always tell your prescriber about prescription, over-the-counter, and herbal products you’re taking.
Patients can also learn more about Zanaflex online while reviewing important treatment details.If you miss a dose of Reglan, take it as soon as you remember if it is reasonably close to the scheduled time. If the next dose is due soon, skip the missed dose and resume your regular dosing schedule. Do not double up to make up for a missed dose, as doing so can increase the risk of adverse effects.
Overdose with metoclopramide can lead to severe central nervous system and cardiorespiratory depression, pronounced extrapyramidal symptoms, hypotension, and in extreme cases coma. If overdose is suspected, seek emergency medical help or contact your local poison control center immediately. Management is largely supportive: maintain airway and hemodynamic stability, treat dystonic reactions with anticholinergics or antihistamines (e.g., diphenhydramine), and use benzodiazepines for agitation or severe EPS. Activated charcoal may be considered if ingestion was recent and supervised by medical personnel.
Store Reglan tablets and oral solutions at room temperature away from excessive heat, moisture, and direct sunlight. Keep the medication in its original container with the lid tightly closed. For injectable formulations, follow label instructions for refrigeration or storage if applicable, and inspect vials for particulate matter or discoloration before use. Keep all medications out of reach of children and pets.
In the United States, Reglan is a prescription medication and should be prescribed by a licensed healthcare provider. Sunshine Pharmacy offers a legal and structured solution for patients who need Reglan but prefer an online pathway: a telehealth consultation with a licensed clinician assesses your symptoms, medical history, and appropriateness of therapy. If deemed appropriate, the clinician issues a valid prescription that Sunshine Pharmacy fills and ships according to federal and state regulations.
This telehealth model allows patients to buy Reglan without prescription in the traditional in-person sense but remains fully compliant with medical and legal standards—prescriptions are only issued after clinical evaluation. Sunshine Pharmacy emphasizes safety: providers screen for contraindications, review concomitant medications, and counsel patients on risks and monitoring. Always verify state-specific regulations and ensure your telehealth provider is licensed for your state.
Reglan carries a boxed warning concerning the risk of tardive dyskinesia with metoclopramide products. To reduce risk, use the lowest effective dose for the shortest possible duration. Monitor patients for the emergence of involuntary movements; if symptoms of tardive dyskinesia appear, discontinue the drug and provide appropriate symptomatic treatment. Clinicians should reassess long-term need and document informed consent when extended therapy is considered.
Be vigilant for signs of acute dystonic reactions, neuroleptic malignant syndrome-like symptoms (fever, muscular rigidity, autonomic instability), severe depression, and suicidal ideation. Educate patients and caregivers about these risks and advise immediate medical attention if they occur. Special populations—elderly patients, pregnant or breastfeeding women, and those with renal impairment—require individualized dosing and closer monitoring.
Before starting Reglan, tell your healthcare provider about all medical conditions, including Parkinson’s disease, depression, seizure disorders, and any history of movement disorders. Provide a complete list of medications, including over-the-counter products, supplements, and herbal remedies. Understand that treatment is typically short-term and that you should report any new or worsening involuntary movements immediately.
Take Reglan exactly as prescribed—usually 30 minutes before meals for motility indications. Avoid alcohol while taking metoclopramide and exercise caution with activities requiring mental alertness until you know how the drug affects you. If you become pregnant, are planning pregnancy, or are breastfeeding, discuss potential risks and alternatives. Keep regular follow-up appointments so your clinician can monitor effectiveness and adverse effects and determine whether continued therapy is appropriate.
Metoclopramide (brand name Reglan) is a dopamine D2-receptor antagonist with prokinetic and antiemetic effects; it’s commonly used short-term to treat diabetic gastroparesis, persistent nausea and vomiting (including chemotherapy- and postoperative-induced), and sometimes as a short-term adjunct in reflux-related symptoms.
Reglan blocks central and peripheral dopamine D2 receptors and has some 5-HT4 agonist activity in the gut, which enhances gastric emptying, increases lower esophageal sphincter tone, and reduces nausea through action on the chemoreceptor trigger zone.
Common side effects include drowsiness, fatigue, restlessness, nausea, diarrhea, and extrapyramidal symptoms such as akathisia or acute dystonia; it can also raise prolactin levels causing galactorrhea or menstrual changes.
Tardive dyskinesia is a potentially irreversible movement disorder characterized by repetitive involuntary movements (often of the face or tongue) that can occur after prolonged dopamine-blocking therapy; Reglan carries a boxed warning for tardive dyskinesia, so use should be limited to the lowest effective dose and shortest duration, typically not beyond 12 weeks unless clearly necessary.
Guidance generally recommends limiting metoclopramide to short-term use, often no longer than 12 weeks, because the risk of tardive dyskinesia and other extrapyramidal side effects increases with duration and cumulative dose; long-term use should be carefully justified and monitored.
These symptoms may represent acute extrapyramidal reactions; patients should stop the medication and seek medical attention promptly—acute dystonia often responds rapidly to intravenous or intramuscular anticholinergics (e.g., benztropine) or antihistamines (e.g., diphenhydramine).
Yes—additive central nervous system depression can occur with alcohol, sedatives, or opioids; concurrent use with other dopamine antagonists (antipsychotics, prochlorperazine) increases extrapyramidal risk; metoclopramide can interact with drugs that affect gastrointestinal motility and may alter absorption of oral medications; dosing adjustments may be needed with renal impairment.
Reglan is sometimes used in pregnancy for nausea after other options fail, but decisions should be individualized with a clinician because safety data are mixed; metoclopramide is excreted in breast milk and can increase prolactin—discuss risks and benefits with a healthcare provider before use during pregnancy or lactation.
Avoid or use with caution in people with a history of tardive dyskinesia or other movement disorders (including Parkinson's disease), those with severe CNS depression or seizure disorders (it can lower seizure threshold), and in significant renal impairment where dose reduction is required; always discuss medical history with a clinician.
Typical adult dosing is 10 mg orally or IV up to four times daily, often given 30 minutes before meals and at bedtime for gastroparesis; IV doses for acute nausea may be used in hospital settings; dosing should be tailored and adjusted for renal impairment.
Monitor for signs of extrapyramidal symptoms, tardive dyskinesia, changes in mood or behavior, excessive sedation, and symptoms of hyperprolactinemia; consider periodic clinical reassessment if therapy continues beyond short-term and renal function monitoring for dose adjustment.
Yes, metoclopramide can increase serum prolactin, potentially causing galactorrhea, breast engorgement, gynecomastia, and menstrual irregularities; these effects usually resolve after stopping the drug but should be evaluated by a clinician.
Symptoms of overdose may include severe drowsiness, extrapyramidal reactions, and possible cardiovascular effects; seek emergency medical care—treatment is supportive, and acute dystonic reactions may be managed with anticholinergic agents or antihistamines per medical guidance.
Antiemetic effects may be noticed within an hour after an oral or IV dose; prokinetic effects on gastric emptying are usually observed with repeated dosing and timing around meals, but individual response varies.
Some patients may experience mood changes, depression, or suicidal ideation while on metoclopramide; any new or worsening mood symptoms should prompt immediate discussion with a healthcare provider.
If discontinuing after short-term use, gradual tapering is not typically required; however, if symptoms of extrapyramidal movement disorders occur, withdrawal and immediate medical evaluation are necessary. Long-term users should be monitored and tapered under clinician direction if concerns exist.
Both are dopamine antagonists used for prokinetic and antiemetic effects; domperidone has less central nervous system penetration and typically causes fewer extrapyramidal side effects but can still raise prolactin and has a notable risk of QT prolongation and cardiac arrhythmias at higher doses; moreover, domperidone is not widely approved in some countries (e.g., limited availability in the U.S.), so choice depends on regulatory status, cardiac risk profile, and clinical goals.
Domperidone tends to cause fewer central extrapyramidal symptoms because it poorly crosses the blood–brain barrier, but it still carries risks (notably cardiac) and raises prolactin; safety must be assessed individually, and cardiac screening (e.g., ECG) may be recommended in at-risk patients.
Erythromycin acts as a motilin receptor agonist producing strong gastric contractions and can be effective for gastroparesis, often used short-term or intravenously in acute settings; however, tachyphylaxis (diminishing effect over time), antibiotic resistance concerns, and QT prolongation limit long-term use, whereas Reglan offers a different mechanism and broader antiemetic benefits but carries movement disorder risks.
Choice depends on clinical context: erythromycin may be preferred for short-term or acute boost of gastric emptying (e.g., in hospital), while Reglan is often tried for symptomatic control in outpatient settings; long-term strategies require careful assessment due to tachyphylaxis (erythromycin) and tardive dyskinesia (metoclopramide).
Cisapride was an effective 5-HT4 agonist prokinetic but was withdrawn or severely restricted in many countries due to serious QT prolongation and fatal arrhythmias, especially with certain drug interactions; Reglan does not share the same level of cardiac risk but has its own serious neurologic risks (tardive dyskinesia), so each drug’s safety profile differs markedly.
Cisapride is largely unavailable or used only under strict, rare-access programs in many regions because of cardiac safety concerns; therefore it is generally not a practical or routine alternative to Reglan in most settings.
Levosulpiride, like metoclopramide, is a benzamide dopamine antagonist used in some countries for dyspepsia and gastroparesis; both can improve gastric motility and increase prolactin, but relative tolerability varies—levosulpiride may have a similar risk of extrapyramidal effects and hyperprolactinemia, so local availability, clinician experience, and individual patient risk determine choice.
Levosulpiride and metoclopramide differ somewhat in pharmacology and regional prescribing patterns; neither is free of central nervous system side effects, and both can cause extrapyramidal symptoms and hyperprolactinemia—careful monitoring is necessary with either agent.
Both are dopamine antagonists effective as antiemetics; prochlorperazine is often used specifically for acute severe nausea and psychotic disorders, while metoclopramide offers the added prokinetic benefit for gastric emptying; both share risks for extrapyramidal symptoms and tardive dyskinesia, so selection is based on indication and patient tolerance.
Ondansetron (a 5-HT3 antagonist) is an effective antiemetic, especially for chemotherapy-induced nausea, and generally lacks the extrapyramidal and tardive dyskinesia risk of Reglan, but it does not have prokinetic effects and can prolong QT interval; choice depends on whether the therapeutic goal is antiemesis alone or also to accelerate gastric emptying.
Metoclopramide has a lower profile of direct cardiac QT-prolonging risk compared with domperidone and erythromycin, both of which can prolong QT and increase arrhythmia risk—cardiac risk assessment is particularly important with domperidone or macrolides, especially in patients on other QT-prolonging drugs or with underlying heart disease.
Options with lower extrapyramidal risk include domperidone (where available and appropriate, with cardiac screening), erythromycin for short-term prokinetic effect, or non-pharmacologic approaches; selection should weigh cardiac, antibiotic resistance, and therapeutic goals, and be guided by a clinician.
Discuss alternative pharmacologic options (e.g., domperidone where accessible, short-term erythromycin), non-pharmacologic measures (dietary modification, small frequent low-fat meals), and advanced interventions (gastric electrical stimulation, enteral feeding) with a gastroenterologist—treatment should be individualized and often multidisciplinary.
